American Airlines shares gain as Q3 results top expectations
Investing.com - Citizens JMP has reiterated its Market Outperform rating and $9.00 price target on Rezolute (NASDAQ:RZLT), following the company’s fiscal fourth-quarter 2025 financial results. The stock, currently trading at $7.71, has shown impressive momentum with a 57.35% gain year-to-date, while analyst targets range from $9 to $17.
The research firm highlighted Rezolute’s continued progress in the clinical development of its hyperinsulinism programs, maintaining its risk-adjusted, DCF-derived price target.
Results for the Phase 3 study evaluating ersodetug in congenital hyperinsulinism (CHI) remain on track for December, which will serve as confirmatory evidence for tumor-associated hyperinsulinism.
Rezolute ended the fiscal year with approximately $168 million in cash, positioning the company with sufficient funding to execute its continued ersodetug development plans.
The company reported its F4Q25 financial results and provided a business update on Wednesday.
In other recent news, Rezolute has received FDA approval for a streamlined Phase 3 upLIFT study, which allows the company to conduct a single-arm, open-label registrational study with up to 16 patients, rather than the initially proposed larger study. This development has led H.C. Wainwright to reiterate a Buy rating on Rezolute, maintaining a price target of $14.00. Additionally, Cantor Fitzgerald has reiterated its Overweight rating on Rezolute, updating its financial model to include the company’s actual earnings from the second and third quarters of fiscal year 2025, along with an April capital raise.
Rezolute has also appointed Sunil Karnawat as Chief Commercial Officer, bringing over 25 years of experience in the global commercialization of biopharmaceuticals and medical devices. Karnawat previously held leadership roles at Cytokinetics and Ultragenyx, where he was instrumental in launching four ultra-rare disease products. Furthermore, Rezolute has posted a patient demographic poster for its ongoing Phase 3 sunRIZE study, making the data available on its website and filing it with the Securities and Exchange Commission. These developments highlight Rezolute’s ongoing efforts in advancing its clinical studies and expanding its leadership team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.